Skip to main content

The Delhi High Court granted an ex parte interim injunction restraining the defendants from marketing VARDENAFIL and VARDENAFIL HYDROCHLORIDE in India.

The court noted that the defendants product contained the plaintiff Bayer’s patented pharmaceutical preparation, but without its permission to exploit the same. The defendants’ drugs, though not commercially launched in India, were being exported to other countries.

Bayer initiated legal proceedings in India upon learning that drugs infringing its patent, valid till 2018, had been seized by customs authorities in Latvia.

Bayer Intellectual Property GmbH v Vipro Lifescience and anr.

Most Recent

News & Insights

VIEW ALL
Thought Leadership
Apr 12, 2025

‘First Published by Managing IP‘ By: Achuthan Sreekumar Achuthan Sreekumar of Anand and Anand draws on a recent High Court of Delhi ruling

Life and death matter? The protection of well-known personal names in India
Thought Leadership
Mar 27, 2025

‘First published on Lexology’ By: Safir Anand and Abhishek Paliwal India, one of the world’s fastest-growing economies, is on track to become a

Company Name vs. Trademark: Essential Insights for Establishing Your Business Brand in India
Thought Leadership
Mar 19, 2025

‘First published on Chambers and Partners’ By: Safir Anand and Twinky Rampal Law and Practice  1. Trade Mark and Copyright Law  1.1 Governing

Chambers Trademarks & Copyright 2025 | Law & Practice
Thought Leadership
Mar 19, 2025

‘First published on Chambers and Partners’ By: Safir Anand Introduction The landscape of intellectual property in India is undergoing a significant

Chambers Trademarks & Copyright 2025 | Trends and Developments